News

JPEO-CBRND Investment Initiates Phase II Clinical Trial Using Tafenoquine to Treat COVID-19
March 12, 2021 — FOR IMMEDIATE RELEASE - The JPM CBRN Medical executed an agreement with 60P to study the effectiveness of an existing drug that shows promise against COVID-19.FORT DETRICK, Md. – February 22, 2021 – The Department of Defense (DOD) awarded a $5 million agreement to 60 Degrees Pharmaceuticals, LLC. (60P), to initiate a Phase II clinical trial to... MORE

American flags against a blue sky background

AstraZeneca to supply US with up to 500,000 additional doses of COVID-19 Long-Acting AntiBody combination AZD7442
March 12, 2021 — Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment... MORE

Biden Administration secures supply of new COVID-19 therapeutic treatment
February 26, 2021 — FOR IMMEDIATE RELEASE - The Biden Administration announced today that it has secured a supply of a recently authorized COVID-19 therapeutic treatment. The U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) collaborated to purchase 100,000 treatment courses of a second therapeutic treatment from Eli Lilly and... MORE

A servicemember sits in a yellow shirt in front of a table of red and blue testing vials. Covi

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function
February 26, 2021 — Link to full article - https://www.prnewswire.com/news-releases/sarpac-clinical-trial-of-leukine-sargramostim-rhu-gm-csf-in-hospitalized-covid-19-patients-meets-primary-endpoint-of-significant-improvement-in-lung-function-301236275.html MORE

Two uniformed service members are in a tent. One wears PPE and a faceshield, while they use a nasal swab to collect a COVID-19 sample from the other Service member in uniform.

Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna
February 12, 2021 — FOR IMMEDIATE RELEASE - The U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) have purchased an additional 100 million doses of COVID-19 vaccines from both Pfizer Inc. and Moderna Inc. to help meet demand for COVID-19 vaccines in the United States.The orders placed today bring the vaccine purchased by the U.S... MORE

The South Carolina National Guard Medical Command receives its first shipment of COVID-19 Moderna vaccinations at McEntire Joint National Guard Base, South Carolina, Dec. 22, 2020. The South Carolina National Guard is a Moderna Department of Defense (DoD) vaccine pilot program state and is provided a limited DoD allocation for South Carolina National Guard Soldiers and Airmen to have the opportunity to voluntarily take the vaccine. The South Carolina National Guard remains ready to support the counties, local and state agencies and first responders with requested resources for as long as needed in support of COVID-19 response efforts in the state.

DOD Awards Industry Partner Immunome $13.3 Million for Biosynthetic Convalescent Plasma Development
February 11, 2021 — The JPM CBRN Medical leveraged an industry partnership to accelerate COVID-19 prevention and treatment research... MORE

DOD Awards $231.8 Million Contract to Ellume USA LLC to Increase Domestic Production Capacity and Deliver COVID-19 Home Tests
February 1, 2021 — FOR IMMEDIATE RELEASE - On Feb. 1, 2021, the Department of Defense (DOD), in coordination with the Department of Health and Human Services, awarded $231.8 million to Ellume USA LLC to onshore production capacity of the Ellume COVID-19 Home Test for the United States.This industrial base expansion effort will allow Ellume USA LLC to increase... MORE

DOD Supports Phase III Clinical Trial Using Fostamatinib (TAVALISSE®) Against COVID-19
January 29, 2021 — The JPM CBRN Medical executed an agreement with Rigel Pharmaceuticals, Inc., to study the effectiveness of TAVALISSE® against COVID-19... MORE

Army Pfc. Christopher Elsberry, assigned to the 36th Medical Company Area Support Battalion, sanitizes a chair inside the mobile COVID-19 testing unit at the Javits Center in New York City, May 19, 2020.

DOD Supports Phase II Clinical Trials Repurposing Inhaled PUL-042 for COVID-19 Prevention and Treatment
January 26, 2021 — The JPM CBRN Medical executed an agreement with Pulmotect, Inc. to study the effectiveness of an existing compound that shows promise against COVID-19... MORE

Increased Collaboration Promotes Improved Medical Diagnostic Capabilities and Health Outcomes
January 25, 2021 — The U.S. Department of Defense (DOD) has a long-standing history of developing medical countermeasures (MCMs) to combat deadly biological threats. Vaccines, diagnostics, and therapeutics serve in a fully-layered continuum of defense capabilities that both protect before exposure as well as to inform and treat after exposure. This set of... MORE

News Search

News Archive - Search by Year and Month

2025 (7)
2024 (40)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

The information contained in these articles has been reviewed and approved for public release.

The appearance of hyperlinks does not constitute endorsement by the JPEO-CBRND of non-U.S. government sites or the information, products, or services contained therein. Although the JPEO-CBRND may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all the information that you may find at these locations. Such hyperlinks are provided consistent with the stated purpose of this website.